Clinical trials: Psilocybin
Prolonged Grief Disorder
Psilocybin for Prolonged Grief Disorder
The primary purpose of this study is to explore the feasibility of conducting a clinical trial on the effects of psilocybin for individuals with prolonged grief disorder (PGD).
- Trial name
- NCT06724289
- Testing
- Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Depression - Major Depressive Disorder, Anhedonia
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1.
- Trial name
- NCT07490353
- Testing
- Psilocybin (Usona Institute), Risperidone 1 MG, MRI
- Where
- Austria
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Treatment Resistant Depression
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
- Trial name
- NCT04433858
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sheppard Pratt Health System
Treatment Resistant Depression, MDD
Psilocybin rTMS for Treatment Resistant Depression
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with…
- Conditions
- Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression
- Trial name
- PSILOBSD (NCT06132178)
- Testing
- Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Cancer
Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer
This pilot project is an open-label trial that will offer psilocybin in a group format to assess the feasibility of offering psilocybin therapy in a group setting with a decreased therapist to subject ratio.
- Trial name
- HOPE (NCT04522804)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Anxiety, Depression
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started…
- Conditions
- Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT07336238
- Testing
- Psychotherapy, Psilocybin, Survey Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Advanced Cancer
Psilocybin Therapy in Advanced Cancer
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of…
- Trial name
- NCT05398484
- Testing
- Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- NYU Langone Health
Alcohol Use Disorder, Alcohol Dependence
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Alcohol Abuse
- Trial name
- Psi or Ket (NCT06405607)
- Testing
- Psilocybin, Ketamine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Iowa
Obsessive - Compulsive Disorder
Psilocybin for Treatment of OCD-2
Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with…
- Trial name
- NCT06992999
- Testing
- Low Dose Psilocybin, High Dose Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Francisco A Moreno
Healthy
Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs
This randomised controlled feasibility trial evaluates the Digital Intervention for Psychedelic Preparation (DIPP), a novel 21-day self-guided program designed to prepare individuals for psychedelic experiences.
- Trial name
- (DIPP-RCFT) (NCT06815653)
- Testing
- Psilocybin 25mg
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University College, London
Advanced Cancer, Stage IV Solid Tumor Cancer
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
- Conditions
- Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma
- Trial name
- NCT06416085
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Alcohol Use Disorder, Alcohol Dependence
Psilocybin-assisted Therapy for Alcohol Use Disorder
To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial.
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Depression, Anxiety
- Trial name
- NCT06444243
- Testing
- Psilocybin, Niacin
- Volunteers
- 90 people
- Sponsor
- University of Sydney
Healthy
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function
This study will test the effects of psilocybin on memory and cognition in healthy participants using computerized tasks and magnetic resonance imaging (MRI).
- Trial name
- NCT07079852
- Testing
- Psilocybin 15mg
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Manoj Doss
Healthy, Psychedelic Experiences
The ENHANCE Study: taVNS and Psilocybin
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance…
- Conditions
- Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
- Trial name
- ENHANCE (NCT05866471)
- Testing
- Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial
- Trial name
- NCT06160232
- Testing
- Psilocybin (high dose)
- Where
- Belgium
- Volunteers
- 62 people
- Sponsor
- Brugmann University Hospital
Alcohol Use Disorder
Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder
This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison…
- Trial name
- NCT07296094
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Brigham and Women's Hospital
Healthy
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research.
- Trial name
- NCT03912974
- Testing
- Escitalopram
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought
This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of…
- Trial name
- NCT05301608
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Autism Spectrum Disorder
Psilocybin in Adults With and Without Autism Spectrum Disorder
This study will test the hypothesis that brain systems are differentially regulated by serotonin in individuals with and without Autism Spectrum Disorder.
- Trial name
- PSILAUT (NCT05651126)
- Testing
- Psilocybin 5 mg, Psilocybin 2 mg
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- King's College London